Prognostic impact of serum 25-hydroxivitamin D [25(OH)D] concentrations in patients with lymphoid malignancies

Figures & data

Figure 1. Median and range of 25(OH)D concentrations were in B-CLL (16.1; 6.6–31.0 ng/ml), in NHL (18.8; 7.5–24.7 ng/ml) and control groups (32.4; 25.0–40.8 ng/ml). There are significant reduction in serum 25(OH)D levels in B-CLL patients and NHL patients as compared with healthy controls (P = 0.00).

Table 1. Association between 25(OH)D concentrations and prognostic markers inB-CLL patients

	Sufficient (> 20 ng/ml )	Insufficient (11–20 ng/ml)	Deficient (≤10 ng/ml)	χ^2	P
	(low risk) n = 21	(high risk) n = 42	(high risk) n = 12
Sex
M	18 (85.7%)	20 (47.6%)	9( 75%)	4.018	0.134
F	3 (14.3%)	22 (52.4%)	3 (25%)
Age
>60 years	6 (28.5%)	18 (42.8%)	3 (25%)	0.663	0.718
≤60 years	15 (71.5%)	24 (57.2%)	9 (75%)
Binet stages
A	9 (42.8%)	0	0	21.134	0.000
B	12 (57.2%)	3 (7.1%)	0
C	0	39 (92.9%)	12 (100%)
ZAP 70
≥ 20%	6 (28.5%)	42 (100%)	12 (100%)	16.644	0.000
< 20%	15 (71.5%)	0	0
CD 38
≥ 30%	6 (28.5%)	42 (100%)	12 (100%)	16.071	0.000
< 30%	15 (71.5%)	0	0

Table 2. Association between 25(OH)D concentrations and prognostic markers of NHL patients

	Sufficient (>20 ng/ml)	Insufficient (11–20 ng/ml)	Deficient (≤10 ng/ml)	χ^2	P
	(low risk) n = 56	(high risk) n = 48	(high risk) n = 16
Sex
M	30 (53.5%)	26 (54.2%)	12 (75%)	0.632	0.729
F	26 (46.5%)	22 (45.8%)	4 (25%)
IPI
1	4 (7.2%)	4 (8.3%)	0	9.212	0.01
2	4 (7.2%)	8 (16.6%)	0
3	20 (35.7%)	12 (25%)	0
4	12 (21.4%)	9 (18.7%)	0
5	16 (28.5%)	15 (31.4%)	4 (100%)
Performance status
1	8 (14.3%)	4 (8.3%)	3 (18.7%)	6.994	0.02
2	12 (21.4%)	8 (16.6%)	3 (18.7%)
3	16 (28.6%)	20 (41.7%)	4 (25%)
4	20 (35.7%)	16 (33.4%)	6 (37.6%)
Clinical stages
I	8 (14.3%)	4 (8.3%)	0	3.115	0.539
II	26 (46.4%)	20(41.7%)	6 (37.5%)
III	22 (39.3%)	24 (50%)	10 (62.5%)

Table 3. Cox regression multivariate analysis of 25(OH)D and other prognostic factors in B-CLL

parameters	HR high risk/low risk	95.0% CI for relative risk		P value
25(OH)D	4.14	1.17	14.58	0.02
Binet stage	1.017	0.297	3.479	0.979
CD 38%	2.20	0.18	26.15	0.52
ZAP 70%	2.50	0.52	11.59	0.23

Table 4. Cox regression multivariate analysis of 25(OH)D and other prognostic factors in NHL

Prameters	HR high risk/low risk	95.0% CI for relative risk		P value
25(OH)D	5.26	1.16	23.8	0.03
Clinical stages	1.94	0.355	10.61	0.44
IPI	4.64	0.963	22.4	0.08
Performance status	3.09	0.279	34.4	0.35

Figure 2. Kaplan–Meier curve for OS in high-risk B-CLL versus low-risk B-CLL patients subgroup. There are significant shortening in the OS in the high-risk group as compared with the low-risk group (P = 0.04).

Figure 3. Kaplan–Meier curve for OS in high-risk NHL subgroup as compared with the low-risk NHL patient's subgroup. There are significant shortening in the OS in high-risk group as compared with the low-risk group (P = 0.01).